This study of the academic and pharma/biotech sectors in North America and Europe will provide suppliers with an analysis of the market for primary cells and an assessment of the brand equity for the leading companies who serve this market
Arlington, VA (PRWEB) May 16, 2013
BioInformatics LLC New Market Report – The Market for Primary Cells & Stem Cell-Derived Cells: Current and Future Opportunities (13-004)
With barriers to entry low, the number of suppliers in the primary cells market continues to increase. In this study, BioInformatics LLC examines what cell types are used most often, how satisfied scientists are with commercially available primary cells, what is the market size and anticipated growth rate.
Additionally, terminally differentiated cells can be used in many applications where primary cells are currently employed. This report profiles this emerging market and the role of commercial suppliers in this area, and explores how the use of primary cells be will be affected by the availability of stem cell-derived differentiated cell types.
Of interest to suppliers is what motivates scientists to purchase primary cells. A key finding in this report indicates that the number one reason that a lab chooses a particular supplier is that the required cell type is available (75%). But not too far behind (54%) is that the product quality is consistent for that particular brand. Additionally, the study finds that the average number of liters per month used to culture primary cells in North American and European labs is 9.95.
The following companies are listed as answer choices in the survey:
BD Gentest (now Corning Life Sciences)
CET (Cell Engineering Technology)
CellnTec Advanced Cell Systems
Gibco (Life Technologies
Lifeline Cell Technology
QBM Cell Science
TRL Triangle Research Labs
“This study of the academic and pharma/biotech sectors in North America and Europe will provide suppliers with an analysis of the market for primary cells and an assessment of the brand equity for the leading companies who serve this market,” says Robin Rothrock, Ph.D., Director of Publications at BioInformatics LLC. “Plus, we have explored the market for stem cell-derived differentiated cells, a potential threat—or opportunity—to suppliers in this market.”
To learn more about The Market for Primary Cells & Stem Cell-Derived Cells: Current and Future Opportunities (13-004), a complimentary Executive Summary is available at:
Download free executive summary
About Bioinformatics LLC
BioInformatics LLC is the premier research and advisory firm serving the life science industry. By leveraging our professional social network of more than 73,000 life scientists, we have supported more than 500 companies and provided insights that lead to better business decisions. Our assignments include assessing the size and attractiveness of markets, optimizing product configurations and pricing, validating corporate acquisitions, measuring customer loyalty, and evaluating brand strength and positioning.
For more information contact:
2111 Wilson Blvd., Suite 250
Arlington, VA 22201
703.778.3080 x13 (phone)